ProCE Banner Activity

IPM 054: Pharmacokinetics of 3-Mo vs 1-Mo Dapivirine Vaginal Ring

Conference Coverage
Slideset

Through a comparative bioavailability approach in the phase I IPM 054, the 3-month dapivirine 100 mg vaginal ring demonstrated pharmacokinetic noninferiority and superiority to the 1-month 25 mg vaginal ring. 

Released: October 11, 2024

Expiration: October 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner